×

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany’s Disco

By Thomson Reuters Nov 19, 2026 | 1:12 AM

By Bhanvi Satija and Siddhi Mahatole

Nov 19 (Reuters) – AbbVie agreed to pay up to $2.54 billion to develop cancer treatments with Disco Pharmaceuticals, the Germany-based private biotech said on ​Thursday, marking an early-stage push by the drugmaker on ‌next-generation bispecific therapies.

Bispecific antibodies, a class of cancer medicines that bind two targets at once, have drawn increased interest from big drugmakers including Bristol Myers Squibb, Pfizer and Merck.

In January, AbbVie paid RemeGen $650 million upfront for rights ‌outside ​China to a bispecific medicine targeting ⁠solid tumors.

Disco will receive $40 million ⁠upfront and up to $2.5 billion in milestone payments as part of the deal to develop so-called AND-gated bispecific therapeutics for solid tumors. It will also be eligible for tiered royalties ​on worldwide net sales.

The approach is designed to recognize cancer cells only when two target proteins are present simultaneously, potentially ⁠reducing damage to healthy tissue.

Disco CEO ⁠Mark Manfredi said his company will be responsible ​for the research and discovery. AbbVie will have the right to ​exclusively license selected programs for further development.

“(AbbVie) brings a ‌wealth of information, a wealth of experience in target biology, so we will learn from them and we will work with them on how to select targets,” said Manfredi.

The deal is at ⁠a very early stage. Disco did not disclose how many programs could be covered or when any could enter clinical development, and AbbVie’s ⁠license option applies only ‌after Disco completes specified research.

Disco has been ⁠developing AND-gated therapies for small-cell lung and colorectal ​cancer, ‌and Manfredi said the company will select a ​development candidate ⁠in the second half of next year.

Other recent bispecific deals include Bristol Myers Squibb’s up to $11.1 billion partnership with BioNTech, Takeda’s multibillion-dollar deal with China’s Innovent and UCB’s $2.2 billion acquisition of Candid Therapeutics.

(Reporting by Siddhi Mahatole in Bengaluru and Bhanvi Satija in London; Editing ​by Sahal Muhammed)